Hybridomas for lung cancer marker and monoclonal antibodies...

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/30 (2006.01) A61K 39/395 (2006.01) C12N 5/20 (2006.01) C12N 9/88 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01)

Patent

CA 2374587

Hybridomas secreting monoclonal antibodies specific for an epitope found in the amino acids of LCGA associated with non-small cell lung carcinoma protein have been found. The monoclonal antibodies produced by these hybridomas can be used in in vivo and in vitro clinical diagnosis of non-small cell lung carcinoma and ovarian carcinoma and as target selective carriers for various anti-tumor agents and radioimaging agents.

La présente invention concerne des hybridomes sécrétant des anticorps monoclonaux spécifiques d'un épitope rencontré dans les acides aminés du LCGA associé à la protéine du carcinome du poumon à cellules non-petites. Les anticorps monoclonaux produits par ces hybridomes conviennent particulièrement, d'une part au diagnostic clinique in vivo et in vitro du carcinome du poumon à cellules non petites, ainsi que du carcinome des ovaires, et d'autre part comme vecteurs sélectifs des cibles pour divers antitumoraux et agents de radio-imagerie.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Hybridomas for lung cancer marker and monoclonal antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybridomas for lung cancer marker and monoclonal antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybridomas for lung cancer marker and monoclonal antibodies... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1724949

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.